Automate Your Wheel Strategy on GMAB
With Tiblio's Option Bot, you can configure your own wheel strategy including GMAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GMAB
- Rev/Share 22.7927
- Book/Share 9.3364
- PB 21.6348
- Debt/Equity 0.0247
- CurrentRatio 6.0337
- ROIC 0.7576
- MktCap 124425564333.123
- FreeCF/Share 4.8608
- PFCF 41.5564
- PE 18.9372
- Debt/Assets 0.0202
- DivYield 0
- ROE 0.2397
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | GMAB | Guggenheim | Neutral | Buy | -- | $43 | Sept. 23, 2025 |
| Downgrade | GMAB | Bernstein | Market Perform | Underperform | -- | -- | April 1, 2025 |
| Upgrade | GMAB | William Blair | Market Perform | Outperform | -- | -- | March 11, 2025 |
| Upgrade | GMAB | Leerink Partners | Market Perform | Outperform | -- | $27 | Feb. 13, 2025 |
| Initiation | GMAB | Redburn Atlantic | -- | Buy | -- | -- | Oct. 8, 2024 |
| Resumed | GMAB | Morgan Stanley | -- | Equal Weight | -- | $31 | Sept. 4, 2024 |
| Downgrade | GMAB | JP Morgan | Overweight | Neutral | -- | -- | Aug. 20, 2024 |
News
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Published: November 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; November 20, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 6,933 restricted stock units and 7,377 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Read More
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; November 19, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,059 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 study that evaluated fixed duration EPKINLY + R2 compared to standard of care R2.i
Read More
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes
Published: November 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market and other conditions, $1.5 billion of senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab also launched the syndication of a new $2.0 billion senior secured term loan “B” facility, which term loan “B” facility is in addition to a $1.0 billion senior secured term loan “A” facility and …
Read More
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; November 3, 2025 More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignancies New data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL) Results from Phase 3 EPCORE FL-1 trial, evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) accepted for oral presentation Genmab A/S (Nasdaq: GMAB ) today announced …
Read More
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Published: November 03, 2025 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin's lymphoma (NHL) subtypes, will be presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH), in Orlando, Florida, and online, December 6-9. Data from the epcoritamab development program will showcase its expan.
Read More
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
Published: October 23, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus N.V. (NasdaqGM: MRUS) to Genmab A/S (NasdaqGS: GMAB). Under the terms of the proposed transaction, shareholders of Merus will receive $97.00 in cash for each share of Merus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe.
Read More
GMAB or TECH: Which Is the Better Value Stock Right Now?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Read More
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
Read More
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Genmab A/S Sponsored ADR (GMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Best Momentum Stock to Buy for October 3rd
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
GFI, GMAB and AEG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2025.
Read More
New Strong Buy Stocks for October 3rd
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
DORM, AEG, GMAB, SCSC and GFI have been added to the Zacks Rank #1 (Strong Buy) List on October 3rd, 2025.
Read More
Major Shareholder Announcement
Published: September 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of September 19, 2025, Orbis Investment Management Limited through shares and ADRs, representing shares, controlled the voting rights to 3,230,732 shares in Genmab A/S, which amounts to 5.03% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement.
Read More
Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff
Published: September 12, 2025 by: Seeking Alpha
Sentiment: Positive
Genmab A/S is leveraging its royalty-centric model and new ADCs like Epkinly to offset upcoming Darzalex patent expiry risks. Epkinly's strong Phase 3 data in follicular lymphoma positions GMAB for blockbuster potential and validates its co-promotion strategy with AbbVie. Despite a recent rally, GMAB remains undervalued versus peers, with robust profitability, cash flow, and a discounted forward P/E ratio.
Read More
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: September 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: September 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference
Published: August 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; August 26, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its Chief Executive Officer Jan Van de Winkel and C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City, NY at 7 : 45 A M E D T ( 1 : 45 PM CE S T ) on September 9 , 202 5 . A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-presentations.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: August 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Genmab (GMAB) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Genmab Announces Financial Results for the First Half of 2025
Published: August 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab a dvancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R 2 in patients with relapsed or refractory FL Rinatabart sesutecan (Rina-S ® ) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data presented at the 2025 ASCO Annual Meeting Data from over 40 abstracts highlighting the depth, breadth and strength of Genmab's comprehensive epcoritamab development program presented at multiple medical conferences Genmab revenue increased 19% compared to the first six …
Read More
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Genmab (GMAB) Upgraded to Strong Buy: Here's Why
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Genmab (GMAB) points to a 40% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Completion of Share Buy-back Program
Published: June 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
Published: June 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Genmab A/S is a high-margin, royalty-driven biotech with a robust pipeline and strong partnerships, notably with J&J, AbbVie, and Pfizer. Darzalex remains the key revenue driver, but patent protection and new indications should sustain growth for at least four more years. The company boasts a rock-solid balance sheet, undervalued metrics (low PE, PEG, high FCF yield), and active share buybacks.
Read More
Transactions in Connection with Share Buy-back Program
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Transactions in Connection with Share Buy-back Program
Published: June 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
About Genmab A/S (GMAB)
- IPO Date 2009-06-01
- Website https://www.genmab.com
- Industry Biotechnology
- CEO Jan G.J. van de Winkel
- Employees 2638